Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

计划入组 492 人 · 首次发布于 2018 年 5 月 4 日

Study Evaluating the Safety and Tolerability of NSA-789

计划入组 64 人 · 首次发布于 2008 年 3 月 11 日

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

计划入组 24 人 · 首次发布于 2008 年 11 月 21 日

LASSBio-789

ADC-789

NSA-789

Sapporo Holdings Ltd.

Japan

SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY

South Africa

Alliance Foundation Trials LLC

United States

KEYNOTE-789: Pembrolizumab Plus Chemotherapy Fails to Improve Survival in EGFR-Mutated NSCLC

Merck Halts Final Phase 3 Keytruda Trial in Prostate Cancer After Failed Interim Analysis

Benmelstobart Plus Anlotinib Shows Promise in EGFR-Mutated NSCLC After TKI Failure